Outset Medical (OM) Stock Forecast, Price Target & Predictions
OM Stock Forecast
Outset Medical stock forecast is as follows: an average price target of $11.00 (represents a 1975.47% upside from OM’s last price of $0.53) and a rating consensus of 'Buy', based on 9 wall street analysts offering a 1-year stock forecast.
OM Price Target
The average price target for Outset Medical (OM) is $11.00 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $34.00 to $3.00. This represents a potential 1975.47% upside from OM's last price of $0.53.
OM Analyst Ratings
According to 9 Wall Street analysts, Outset Medical's rating consensus is 'Buy'. The analyst rating breakdown for OM stock is 0 'Strong Buy' (0.00%), 6 'Buy' (66.67%), 3 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Outset Medical Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 08, 2024 | Shagun Singh | RBC Capital | $3.00 | $3.40 | -11.76% | 466.04% |
| Jun 21, 2024 | Shagun Singh | RBC Capital | $6.00 | $3.58 | 67.36% | 1032.08% |
| Apr 17, 2024 | Rick Wise | Stifel Nicolaus | $6.00 | $2.27 | 164.32% | 1032.08% |
| Apr 08, 2024 | Maria Thibault | BTIG | $6.00 | $2.05 | 192.68% | 1032.08% |
| Apr 05, 2024 | Kristen Stewart | C.L. King | $6.00 | $1.94 | 209.28% | 1032.08% |
| Nov 11, 2022 | - | RBC Capital | $23.00 | $17.51 | 31.35% | 4239.62% |
| Aug 03, 2022 | - | Goldman Sachs | $34.00 | $19.45 | 74.76% | 6315.09% |
| Jul 18, 2022 | - | Stifel Nicolaus | $24.00 | $16.91 | 41.89% | 4428.30% |
| Jun 14, 2022 | - | Stifel Nicolaus | $30.00 | $20.41 | 46.99% | 5560.38% |
The latest Outset Medical stock forecast, released on Aug 08, 2024 by Shagun Singh from RBC Capital, set a price target of $3.00, which represents a -11.76% decrease from the stock price at the time of the forecast ($3.40), and a 466.04% increase from OM last price ($0.53).
Outset Medical Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 5 |
| Avg Price Target | - | $4.50 | $5.40 |
| Last Closing Price | $0.53 | $0.53 | $0.53 |
| Upside/Downside | -100.00% | 749.06% | 918.87% |
In the current month, the average price target of Outset Medical stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Outset Medical's last price of $0.53. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 08, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 08, 2024 | RBC Capital | Outperform | Sector Perform | Downgrade |
| Jun 21, 2024 | RBC Capital | Sector Perform | Outperform | Upgrade |
| Apr 08, 2024 | BTIG | - | Buy | Initialise |
| Aug 17, 2023 | UBS | - | Neutral | Initialise |
| Aug 17, 2023 | RBC Capital | Outperform | Sector Perform | Initialise |
| Aug 17, 2023 | BMO Capital | - | Outperform | Initialise |
| Aug 17, 2023 | Jefferies | - | Buy | Initialise |
| Aug 17, 2023 | Morgan Stanley | - | Equal-Weight | Initialise |
| Aug 17, 2023 | Piper Sandler | - | Overweight | Initialise |
Outset Medical's last stock rating was published by Cowen & Co. on Aug 08, 2024. The company gave OM a "Buy" rating, the same as its previous rate.
Outset Medical Financial Forecast
Outset Medical Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $30.36M | $36.04M | $33.47M | $32.01M | $27.76M | - | $30.55M | $28.15M | $26.32M | $25.22M | $22.92M | $17.25M | $13.76M |
| Avg Forecast | $46.50M | $42.73M | $40.86M | $37.96M | $33.87M | $32.26M | $30.56M | $29.28M | $27.77M | $26.84M | $31.17M | $30.35M | $30.50M | $30.39M | $34.79M | $31.75M | $30.92M | $25.22M | $27.50M | $30.11M | $26.43M | $25.13M | $23.73M | $21.45M | $13.76M | $11.53M |
| High Forecast | $47.36M | $43.52M | $41.62M | $38.66M | $34.50M | $32.86M | $31.13M | $29.82M | $28.28M | $26.98M | $31.75M | $30.91M | $30.62M | $30.40M | $35.44M | $32.34M | $31.49M | $25.69M | $27.50M | $31.49M | $27.64M | $26.28M | $24.81M | $22.43M | $14.39M | $12.06M |
| Low Forecast | $45.29M | $41.61M | $39.79M | $36.97M | $32.99M | $31.42M | $29.77M | $28.52M | $27.04M | $26.57M | $30.36M | $29.56M | $30.40M | $30.35M | $33.89M | $30.92M | $30.12M | $24.56M | $27.50M | $28.66M | $25.16M | $23.92M | $22.59M | $20.42M | $13.10M | $10.98M |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 6 | 3 | 3 | 4 | 4 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00% | 1.04% | 1.05% | 1.04% | 1.10% | - | 1.01% | 1.07% | 1.05% | 1.06% | 1.07% | 1.25% | 1.19% |
Outset Medical's average Quarter revenue forecast for Dec 23 based on 3 analysts is $30.50M, with a low forecast of $30.40M, and a high forecast of $30.62M. OM's average Quarter revenue forecast represents a 0.45% increase compared to the company's last Quarter revenue of $30.36M (Sep 23).
Outset Medical EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 6 | 3 | 3 | 4 | 4 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-45.45M | $-43.48M | $-40.84M | $-37.92M | $-40.19M | - | $-35.09M | $-40.68M | $-28.73M | $-28.43M | $-28.32M | $-29.68M | $-41.43M |
| Avg Forecast | $-46.50M | $-42.73M | $-40.86M | $-37.96M | $-33.87M | $-32.26M | $-30.56M | $-29.28M | $-27.77M | $-26.84M | $-31.17M | $-38.92M | $-30.50M | $-30.39M | $-34.79M | $-35.39M | $-30.92M | $-32.93M | $-27.50M | $-32.17M | $-38.72M | $-35.22M | $-32.18M | $-31.86M | $-13.76M | $-38.62M |
| High Forecast | $-45.29M | $-41.61M | $-39.79M | $-36.97M | $-32.99M | $-31.42M | $-29.77M | $-28.52M | $-27.04M | $-26.57M | $-30.36M | $-31.14M | $-30.40M | $-30.35M | $-33.89M | $-28.31M | $-30.12M | $-26.35M | $-27.50M | $-25.73M | $-30.97M | $-28.18M | $-25.74M | $-25.49M | $-13.10M | $-30.90M |
| Low Forecast | $-47.36M | $-43.52M | $-41.62M | $-38.66M | $-34.50M | $-32.86M | $-31.13M | $-29.82M | $-28.28M | $-26.98M | $-31.75M | $-46.71M | $-30.62M | $-30.40M | $-35.44M | $-42.46M | $-31.49M | $-39.52M | $-27.50M | $-38.60M | $-46.46M | $-42.27M | $-38.61M | $-38.23M | $-14.39M | $-46.35M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.50% | 1.25% | 1.15% | 1.23% | 1.22% | - | 1.09% | 1.05% | 0.82% | 0.88% | 0.89% | 2.16% | 1.07% |
undefined analysts predict OM's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Outset Medical's previous annual EBITDA (undefined) of $NaN.
Outset Medical Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 6 | 3 | 3 | 4 | 4 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-46.18M | $-44.05M | $-43.97M | $-41.44M | $-40.78M | - | $-36.89M | $-41.23M | $-30.47M | $-30.21M | $-30.02M | $-32.04M | $-42.29M |
| Avg Forecast | $-14.65M | $-15.93M | $-17.19M | $-18.34M | $-17.47M | $-18.33M | $-18.90M | $-19.34M | $-20.75M | $-22.83M | $-23.15M | $-40.92M | $-33.20M | $-36.46M | $-39.17M | $-37.20M | $-40.81M | $-34.93M | $-32.37M | $-33.82M | $-39.24M | $-37.36M | $-34.18M | $-33.78M | $-33.37M | $-39.43M |
| High Forecast | $-14.16M | $-15.39M | $-16.61M | $-17.72M | $-16.88M | $-17.71M | $-18.26M | $-18.69M | $-20.05M | $-20.11M | $-22.37M | $-32.74M | $-29.94M | $-31.02M | $-37.84M | $-29.76M | $-39.43M | $-27.95M | $-32.37M | $-27.05M | $-31.40M | $-29.89M | $-27.35M | $-27.02M | $-31.29M | $-31.54M |
| Low Forecast | $-15.00M | $-16.31M | $-17.60M | $-18.79M | $-17.89M | $-18.77M | $-19.36M | $-19.81M | $-21.25M | $-25.00M | $-23.71M | $-49.10M | $-35.92M | $-39.19M | $-40.12M | $-44.64M | $-41.80M | $-41.92M | $-32.37M | $-40.58M | $-47.09M | $-44.83M | $-41.02M | $-40.53M | $-35.36M | $-47.31M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.27% | 1.12% | 1.18% | 1.02% | 1.17% | - | 1.09% | 1.05% | 0.82% | 0.88% | 0.89% | 0.96% | 1.07% |
Outset Medical's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. OM's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Outset Medical SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 6 | 3 | 3 | 4 | 4 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $36.53M | $36.27M | $36.12M | $33.65M | $32.28M | - | $30.09M | $32.71M | $23.36M | $22.93M | $22.39M | $24.25M | $26.43M |
| Avg Forecast | $61.83M | $56.81M | $54.33M | $50.47M | $45.04M | $42.90M | $40.64M | $38.93M | $36.92M | $35.69M | $41.45M | $40.36M | $40.56M | $40.41M | $46.27M | $30.34M | $41.11M | $33.54M | $36.56M | $27.58M | $35.14M | $33.41M | $31.55M | $28.52M | $18.30M | $15.34M |
| High Forecast | $62.98M | $57.87M | $55.34M | $51.41M | $45.88M | $43.70M | $41.39M | $39.66M | $37.61M | $35.87M | $42.22M | $41.11M | $40.72M | $40.43M | $47.13M | $36.40M | $41.88M | $34.16M | $36.56M | $33.09M | $36.75M | $34.94M | $32.99M | $29.83M | $19.14M | $16.04M |
| Low Forecast | $60.22M | $55.34M | $52.92M | $49.16M | $43.87M | $41.78M | $39.58M | $37.92M | $35.96M | $35.33M | $40.37M | $39.31M | $40.42M | $40.36M | $45.06M | $24.27M | $40.04M | $32.66M | $36.56M | $22.06M | $33.46M | $31.81M | $30.04M | $27.16M | $17.42M | $14.60M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.90% | 0.78% | 1.19% | 0.82% | 0.96% | - | 1.09% | 0.93% | 0.70% | 0.73% | 0.79% | 1.33% | 1.72% |
Outset Medical's average Quarter SG&A projection for Dec 23 is $40.56M, based on 3 Wall Street analysts, with a range of $40.42M to $40.72M. The forecast indicates a 11.01% rise compared to OM last annual SG&A of $36.53M (Sep 23).
Outset Medical EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 6 | 3 | 3 | 4 | 4 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.93 | $-0.90 | $-0.90 | $-0.86 | $-0.85 | - | $-0.78 | $-0.87 | $-0.65 | $-0.66 | $-0.70 | $-0.75 | $-3.44 |
| Avg Forecast | $-0.28 | $-0.31 | $-0.33 | $-0.35 | $-0.34 | $-0.35 | $-0.36 | $-0.37 | $-0.40 | $-0.44 | $-0.45 | $-0.55 | $-0.64 | $-0.70 | $-0.76 | $-0.73 | $-0.79 | $-0.75 | $-0.64 | $-0.68 | $-0.71 | $-0.71 | $-0.69 | $-0.80 | $-0.66 | $-2.27 |
| High Forecast | $-0.27 | $-0.30 | $-0.32 | $-0.34 | $-0.33 | $-0.34 | $-0.35 | $-0.36 | $-0.39 | $-0.39 | $-0.43 | $-0.53 | $-0.58 | $-0.60 | $-0.73 | $-0.71 | $-0.76 | $-0.72 | $-0.64 | $-0.64 | $-0.67 | $-0.67 | $-0.64 | $-0.75 | $-0.62 | $-2.13 |
| Low Forecast | $-0.29 | $-0.31 | $-0.34 | $-0.36 | $-0.34 | $-0.36 | $-0.37 | $-0.38 | $-0.41 | $-0.48 | $-0.46 | $-0.56 | $-0.69 | $-0.76 | $-0.77 | $-0.75 | $-0.81 | $-0.76 | $-0.64 | $-0.72 | $-0.75 | $-0.76 | $-0.73 | $-0.85 | $-0.70 | $-2.41 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.32% | 1.19% | 1.23% | 1.09% | 1.14% | - | 1.14% | 1.23% | 0.91% | 0.96% | 0.87% | 1.13% | 1.51% |
According to undefined Wall Street analysts, Outset Medical's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to OM previous annual EPS of $NaN (undefined).
Outset Medical Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| OM | Outset Medical | $0.53 | $11.00 | 1975.47% | Buy |
| NVRO | Nevro | $5.79 | $32.99 | 469.78% | Hold |
| CVRX | CVRx | $7.85 | $15.83 | 101.66% | Buy |
| OFIX | Orthofix Medical | $16.76 | $31.00 | 84.96% | - |
| NPCE | NeuroPace | $7.43 | $12.88 | 73.35% | Buy |
| NARI | Inari Medical | $46.52 | $72.88 | 56.66% | Buy |
| SGHT | Sight Sciences | $6.95 | $10.33 | 48.63% | Hold |
| LUNG | Pulmonx | $8.31 | $12.25 | 47.41% | Buy |
| CNMD | CONMED | $75.40 | $101.00 | 33.95% | Buy |
| SIBN | SI-BONE | $15.73 | $20.00 | 27.15% | Buy |
| KIDS | OrthoPediatrics | $32.28 | $40.80 | 26.39% | Buy |
| INSP | Inspire Medical Systems | $203.99 | $237.80 | 16.57% | Buy |
| CLPT | ClearPoint Neuro | $12.59 | $12.00 | -4.69% | Buy |
| SWAV | ShockWave Medical | $334.75 | $258.17 | -22.88% | Hold |
OM Forecast FAQ
Is Outset Medical a good buy?
Yes, according to 9 Wall Street analysts, Outset Medical (OM) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 66.67% of OM's total ratings.
What is OM's price target?
Outset Medical (OM) average price target is $11 with a range of $3 to $34, implying a 1975.47% from its last price of $0.53. The data is based on 9 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Outset Medical stock go up soon?
According to Wall Street analysts' prediction for OM stock, the company can go up by 1975.47% (from the last price of $0.53 to the average price target of $11), up by 6315.09% based on the highest stock price target, and up by 466.04% based on the lowest stock price target.
Can Outset Medical stock reach $1?
OM's average twelve months analyst stock price target of $11 supports the claim that Outset Medical can reach $1 in the near future.
What are Outset Medical's analysts' financial forecasts?
Outset Medical's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $125.97M (high $128.32M, low $122.7M), average EBITDA is $-126M (high $-123M, low $-128M), average net income is $-74.041M (high $-71.536M, low $-75.83M), average SG&A $167.51M (high $170.62M, low $163.15M), and average EPS is $-1.427 (high $-1.379, low $-1.462). OM's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $168.04M (high $171.16M, low $163.66M), average EBITDA is $-168M (high $-164M, low $-171M), average net income is $-66.111M (high $-63.874M, low $-67.708M), average SG&A $223.44M (high $227.59M, low $217.63M), and average EPS is $-1.274 (high $-1.231, low $-1.305).
Did the OM's actual financial results beat the analysts' financial forecasts?
Based on Outset Medical's last annual report (Dec 2022), the company's revenue was $115.38M, beating the average analysts forecast of $113.74M by 1.43%. Apple's EBITDA was $-158M, beating the average prediction of $-124M by 27.70%. The company's net income was $-163M, beating the average estimation of $-142M by 14.81%. Apple's SG&A was $130M, missing the average forecast of $138.79M by -6.34%. Lastly, the company's EPS was $-3.38, beating the average prediction of $-2.852 by 18.51%. In terms of the last quarterly report (Sep 2023), Outset Medical's revenue was $30.36M, missing the average analysts' forecast of $30.39M by -0.10%. The company's EBITDA was $-45.454M, beating the average prediction of $-30.391M by 49.56%. Outset Medical's net income was $-46.18M, beating the average estimation of $-36.464M by 26.64%. The company's SG&A was $36.54M, missing the average forecast of $40.41M by -9.59%. Lastly, the company's EPS was $-0.93, beating the average prediction of $-0.703 by 32.32%